SCHEMBL7140660

SCHEMBL7140660

CCN(C)Cc1c[c]ccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 1/20 0.50
CHRNA4 P43681 1/20 0.50
CARM1 Q86X55 1/20 0.36
PRMT6 Q96LA8 1/20 0.36
PRMT8 Q9NR22 1/20 0.36
TSHR P16473 3/20 0.35
LMNA P02545 2/20 0.35
CYP3A4 P08684 2/20 0.35
USP2 O75604 1/20 0.35
MAOA P21397 1/20 0.35
MAOB P27338 1/20 0.35
PYCR1 P32322 1/20 0.35
ALDH1A1 P00352 4/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
BLM P54132 1/20 0.34
LTA4H P09960 1/20 0.34
KDM4E B2RXH2 2/20 0.33
SIGMAR1 Q99720 1/20 0.33
ACHE P22303 1/20 0.33
CYP1A2 P05177 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6634828 0.85 CARM1 (0.42) CHRNB2CHRNA4CARM1PRMT6PRMT8
SCHEMBL2645309 0.85 ALDH1A1 (0.49) CARM1PRMT6PRMT8TSHRLMNA
SCHEMBL6235591 0.82 HRH3 (0.47) TSHRMAOBKDM4ECYP1A2CYP2D6
SCHEMBL1041217 0.82 TSHR (0.54) CHRNB2CHRNA4TSHRALDH1A1ACHE
SCHEMBL6638418 0.80 SIGMAR1 (0.49) CARM1PRMT6PRMT8MAOAMAOB
SCHEMBL6634552 0.78 ADRA2B (0.44) TSHRMAOAMAOBPYCR1ALDH1A1
SCHEMBL6637319 0.78 BCHE (0.35) TSHRKDM4ESIGMAR1
SCHEMBL27947941 0.78 CARM1 (0.50) CARM1PRMT6PRMT8LMNAMAOA
SCHEMBL6667357 0.77 HRH3 (0.43) TSHRMAOBKDM4E
SCHEMBL5375507 0.76 ALDH1A1 (0.33) TSHRCYP3A4ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6515133-B1 Certain diaryl imidazoles act as partial agonists or antagonists for NPY receptors, in particular NPY 5 receptors. They are of use, for example in treating loss of appetite. Such compounds bear aryl groups in the 2 position. NEUROGEN CORPORATION 2003-02-04 US claimed
US-6121260-A Method of treating conditions susceptible to modulation of NPY receptors with diarylimidazole derivatives NEUROGEN CORPORATION (US) 2000-09-19 US claimed
EP-0996443-A1 CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 2000-05-03 EP claimed
WO-1999001128-A1 CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 1999-01-14 WO claimed
US-6515133-B1 Certain diaryl imidazoles act as partial agonists or antagonists for NPY receptors, in particular NPY 5 receptors. They are of use, for example in treating loss of appetite. Such compounds bear aryl groups in the 2 position. NEUROGEN CORPORATION 2003-02-04 US disclosed
US-6121260-A Method of treating conditions susceptible to modulation of NPY receptors with diarylimidazole derivatives NEUROGEN CORPORATION (US) 2000-09-19 US disclosed
EP-0996443-A1 CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 2000-05-03 EP disclosed
WO-1999001128-A1 CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS NEUROGEN CORPORATION (US) 1999-01-14 WO disclosed